PURPOSE: To understand the mechanism through which obesity in breast cancer patients is associated with poorer outcome, we evaluated body mass index (BMI) and response to neoadjuvant chemotherapy (NC) in women with operable breast cancer. PATIENTS AND METHODS: From May 1990 to July 2004, 1,169 patients were diagnosed with invasive breast cancer at M. D. Anderson Cancer Center and received NC before surgery. Patients were categorized as obese (BMI >or= 30 kg/m(2)), overweight (BMI of 25 to < 30 kg/m(2)), or normal/underweight (BMI < 25 kg/m(2)). Logistic regression was used to examine associations between BMI and pathologic complete response (pCR). Breast cancer-specific, progression-free, and overall survival times were examined using the Kaplan-Meier method and Cox proportional hazards regression analysis. All statistical tests were two-sided. RESULTS: Median age was 50 years; 30% of patients were obese, 32% were overweight, and 38% were normal or underweight. In multivariate analysis, there was no significant difference in pCR for obese compared with normal weight patients (odds ratio [OR] = 0.78; 95% CI, 0.49 to 1.26). Overweight and the combination of overweight and obese patients were significantly less likely to have a pCR (OR = 0.59; 95% CI, 0.37 to 0.95; and OR = 0.67; 95% CI, 0.45 to 0.99, respectively). Obese patients were more likely to have hormone-negative tumors (P < .01), stage III tumors (P < .01), and worse overall survival (P = .006) at a median follow-up time of 4.1 years. CONCLUSION: Higher BMI was associated with worse pCR to NC. In addition, its association with worse overall survival suggests that greater attention should be focused on this risk factor to optimize the care of breast cancer patients.
PURPOSE: To understand the mechanism through which obesity in breast cancerpatients is associated with poorer outcome, we evaluated body mass index (BMI) and response to neoadjuvant chemotherapy (NC) in women with operable breast cancer. PATIENTS AND METHODS: From May 1990 to July 2004, 1,169 patients were diagnosed with invasive breast cancer at M. D. Anderson Cancer Center and received NC before surgery. Patients were categorized as obese (BMI >or= 30 kg/m(2)), overweight (BMI of 25 to < 30 kg/m(2)), or normal/underweight (BMI < 25 kg/m(2)). Logistic regression was used to examine associations between BMI and pathologic complete response (pCR). Breast cancer-specific, progression-free, and overall survival times were examined using the Kaplan-Meier method and Cox proportional hazards regression analysis. All statistical tests were two-sided. RESULTS: Median age was 50 years; 30% of patients were obese, 32% were overweight, and 38% were normal or underweight. In multivariate analysis, there was no significant difference in pCR for obese compared with normal weight patients (odds ratio [OR] = 0.78; 95% CI, 0.49 to 1.26). Overweight and the combination of overweight and obesepatients were significantly less likely to have a pCR (OR = 0.59; 95% CI, 0.37 to 0.95; and OR = 0.67; 95% CI, 0.45 to 0.99, respectively). Obesepatients were more likely to have hormone-negative tumors (P < .01), stage III tumors (P < .01), and worse overall survival (P = .006) at a median follow-up time of 4.1 years. CONCLUSION: Higher BMI was associated with worse pCR to NC. In addition, its association with worse overall survival suggests that greater attention should be focused on this risk factor to optimize the care of breast cancerpatients.
Authors: James J Dignam; Kelly Wieand; Karen A Johnson; Bernard Fisher; Lei Xu; Eleftherios P Mamounas Journal: J Natl Cancer Inst Date: 2003-10-01 Impact factor: 13.506
Authors: L Wasserman; S W Flatt; L Natarajan; G Laughlin; M Matusalem; S Faerber; C L Rock; E Barrett-Connor; J P Pierce Journal: Int J Obes Relat Metab Disord Date: 2004-01
Authors: G Berclaz; S Li; K N Price; A S Coates; M Castiglione-Gertsch; C-M Rudenstam; S B Holmberg; J Lindtner; D Erien; J Collins; R Snyder; B Thürlimann; M F Fey; C Mendiola; I Dudley Werner; E Simoncini; D Crivellari; R D Gelber; A Goldhirsch Journal: Ann Oncol Date: 2004-06 Impact factor: 32.976
Authors: Amal Melhem-Bertrandt; Mariana Chavez-Macgregor; Xiudong Lei; Erika N Brown; Richard T Lee; Funda Meric-Bernstam; Anil K Sood; Suzanne D Conzen; Gabriel N Hortobagyi; Ana-Maria Gonzalez-Angulo Journal: J Clin Oncol Date: 2011-05-31 Impact factor: 44.544
Authors: Rachna Raman; Sarah L Mott; Mary C Schroeder; Sneha Phadke; Jad El Masri; Alexandra Thomas Journal: Clin Breast Cancer Date: 2016-06-23 Impact factor: 3.225
Authors: Dan T Vogl; Tao Wang; Waleska S Pérez; Edward A Stadtmauer; Daniel F Heitjan; Hillard M Lazarus; Robert A Kyle; Ram Kamble; Daniel Weisdorf; Vivek Roy; John Gibson; Karen Ballen; Leona Holmberg; Asad Bashey; Philip L McCarthy; Cesar Freytes; Dipnarine Maharaj; Angelo Maiolino; David Vesole; Parameswaran Hari Journal: Biol Blood Marrow Transplant Date: 2011-05-11 Impact factor: 5.742
Authors: Oluwadamilola M Fayanju; Carolyn S Hall; Jessica Bowman Bauldry; Mandar Karhade; Lily M Valad; Henry M Kuerer; Sarah M DeSnyder; Carlos H Barcenas; Anthony Lucci Journal: Am J Surg Date: 2017-06-23 Impact factor: 2.565
Authors: Xiaoli Chen; Wei Lu; Wei Zheng; Kai Gu; Zhi Chen; Ying Zheng; Xiao Ou Shu Journal: Breast Cancer Res Treat Date: 2010-01-08 Impact factor: 4.872
Authors: Erica T Warner; Karla V Ballman; Carrie Strand; Judy C Boughey; Aman U Buzdar; Lisa A Carey; William M Sikov; Ann H Partridge Journal: Breast Cancer Res Treat Date: 2016-07-22 Impact factor: 4.872
Authors: Lesley A Stead; Timothy L Lash; Jerome E Sobieraj; Dorcas D Chi; Jennifer L Westrup; Marjory Charlot; Rita A Blanchard; John C Lee; Thomas C King; Carol L Rosenberg Journal: Breast Cancer Res Date: 2009-03-25 Impact factor: 6.466